Personalis SG&A Expenses 2018-2024 | PSNL

Personalis sg&a expenses from 2018 to 2024. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
Personalis Annual SG&A Expenses
(Millions of US $)
2023 $50
2022 $64
2021 $48
2020 $34
2019 $22
2018 $11
2017 $10
Personalis Quarterly SG&A Expenses
(Millions of US $)
2024-06-30 $12
2024-03-31 $12
2023-12-31 $12
2023-09-30 $12
2023-06-30 $12
2023-03-31 $14
2022-12-31 $18
2022-09-30 $15
2022-06-30 $16
2022-03-31 $15
2021-12-31 $14
2021-09-30 $12
2021-06-30 $11
2021-03-31 $10
2020-12-31 $11
2020-09-30 $8
2020-06-30 $8
2020-03-31 $7
2019-12-31 $6
2019-09-30 $6
2019-06-30 $5
2019-03-31 $4
2018-12-31
2018-09-30 $3
2018-06-30 $3
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.278B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Supernus Pharmaceuticals (SUPN) United States $2.089B 28.44
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00